Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Status:
Suspended
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular
imaging agent in patients with Head and Neck Squamous Cell Carcinoma.
The secondary objective is to compare sensitivity and specificity of identifying sentinel
lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus
conventional local injection with an optical dye at the time of surgery.